Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9588889 | 0.86 | NPC1 (0.70) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL15516309 | 0.86 | NPC1 (0.66) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL1163050 | 0.85 | NPC1 (0.64) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL6443587 | 0.85 | NPC1 (0.58) | NPC1RAB9APOLBMGLLMAOB | |
| SCHEMBL2559038 | 0.82 | NPC1 (0.61) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL8705480 | 0.82 | NPC1 (0.61) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL3083502 | 0.82 | NPC1 (0.60) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL6978900 | 0.82 | NPC1 (0.57) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL3928121 | 0.81 | NPC1 (0.68) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL6923337 | 0.81 | NPC1 (0.59) | NPC1RAB9APOLBCASP3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | NPC1 335/4885RAB9A 1576/4885POLB 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.